PT  - JOURNAL ARTICLE
AU  - Cunningham, Muriel
ED  - Kimmel, Stephen E.
TI  - COAG Trial: No Advantage Seen with Genetic-Based Warfarin Dosing
DP  - 2013  01
TA  - MD Conference Express
PG  - 22--22
VI  - 13
IP  - 20
4099  - http://mdc.sagepub.com/content/13/20/22.1.short
4100  - http://mdc.sagepub.com/content/13/20/22.1.full
AB  - Warfarin is a widely used medication with a very narrow therapeutic window. Limited evidence suggests that utilizing pharmacogenetic information on top of clinical information could improve warfarin dosing, but large, well-conducted studies are lacking. This article discusses the key results of the Clarification of Optimal Anticoagulation Through Genetics trial [COAG; Kimmel SE et al. N Engl J Med 2013], which compared warfarin initiation using a clinical algorithm with or without the addition of pharmacogenetic information.